Search Results - "Garon, E. B."

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer by Kindler, H.L., Richards, D.A., Garbo, L.E., Garon, E.B., Stephenson, J.J., Rocha-Lima, C.M., Safran, H., Chan, D., Kocs, D.M., Galimi, F., McGreivy, J., Bray, S.L., Hei, Y., Feigal, E.G., Loh, E., Fuchs, C.S.

“…We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death…”
Get full text

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis by Ponce Aix, S, Novello, S, Garon, EB, Nakagawa, K, Nadal, E, Moro-Sibilot, D, Alonso Garcia, M, Fabre, E, Frimodt-Moller, B, Zimmermann, AH, Visseren-Grul, CM, Reck, M

“…•Ramucirumab+erlotinib showed superior PFS over placebo+erlotinib in the RELAY trial.•Activating EGFR mutations are less prevalent in Western…”
Get full text

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 by Rodríguez-Abreu, D., Powell, S.F., Hochmair, M.J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S.Y., Bischoff, H.G., Peled, N., Reck, M., Hui, R., Garon, E.B., Boyer, M., Kurata, T., Yang, J., Pietanza, M.C., Souza, F., Garassino, M.C.

“…In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved…”
Get full text

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer by Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

“…Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however,…”
Get full text

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial by Hui, R., Garon, E.B., Goldman, J.W., Leighl, N.B., Hellmann, M.D., Patnaik, A., Gandhi, L., Eder, J.P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G.M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N.A.

“…Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1)…”
Get full text

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer by Giaccone, G, Bazhenova, L.A, Nemunaitis, J, Tan, M, Juhász, E, Ramlau, R, van den Heuvel, M.M, Lal, R, Kloecker, G.H, Eaton, K.D, Chu, Q, Dunlop, D.J, Jain, M, Garon, E.B, Davis, C.S, Carrier, E, Moses, S.C, Shawler, D.L, Fakhrai, H

“…Abstract Background Treatment options after first-line chemotherapy are limited in non-small cell lung cancer (NSCLC). Belagenpumatucel-L is a therapeutic…”
Get full text

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab by Arnold, D., Fuchs, C.S., Tabernero, J., Ohtsu, A., Zhu, A.X., Garon, E.B., Mackey, J.R., Paz-Ares, L., Baron, A.D., Okusaka, T., Yoshino, T., Yoon, H.H., Das, M., Ferry, D., Zhang, Y., Lin, Y., Binder, P., Sashegyi, A., Chau, I.

“…Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for…”
Get full text

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial by Herbst, R.S., Baas, P., Perez-Gracia, J.L., Felip, E., Kim, D.-W., Han, J.-Y., Molina, J.R., Kim, J.-H., Dubos Arvis, C., Ahn, M.-J., Majem, M., Fidler, M.J., Surmont, V., de Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E.H., Lubiniecki, G.M., Garon, E.B.

“…In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced…”
Get full text

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer by Chatterjee, M., Turner, D.C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E.B., Hui, R., Arkenau, H.-T., Gubens, M.A., Hellmann, M.D., Dong, D., Li, C., Mayawala, K., Freshwater, T., Ahamadi, M., Stone, J., Lubiniecki, G.M., Zhang, J., Im, E., De Alwis, D.P., Kondic, A.G., Fløtten, Ø.

“…In the phase I KEYNOTE-001 study, pembrolizumab demonstrated durable antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). We sought…”
Get full text

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer by Lacouture, M.E., Keefe, D.M., Sonis, S., Jatoi, A., Gernhardt, D., Wang, T., Doherty, J.P., Giri, N., Nadanaciva, S., O'Connell, J., Sbar, E., Piperdi, B., Garon, E.B.

“…ARCHER 1042, a randomized phase II trial, explored the impact of prophylactic treatment on select dermatologic adverse events of interest (SDAEI), diarrhea,…”
Get full text

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results by Garon, E.B., Reck, M., Nishio, K., Heymach, J.V., Nishio, M., Novello, S., Paz-Ares, L., Popat, S., Aix, S. Ponce, Graham, H., Butts, B.D., Visseren-Grul, C., Nakagawa, K.

“…Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo + ERL (PBO + ERL) in the phase III RELAY study of…”
Get full text

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC) by Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E.B., Groen, H.J.M., Tan, D.S., Hida, T., de Jonge, M.J.A., Orlov, S.V., Smit, E.F., Souquet, P.-J., Vansteenkiste, J.F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., Heist, R.S.

Get full text

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC by Cho, B.C., Reinmuth, N., Lee, K.H., Ahn, M.-J., Luft, A., Van den Heuvel, M., Dols, M. Cobo, Smolin, A., Vicente, D., Moiseyenko, V., Antonia, S.J., Moulec, S. Le, Robinet, G., Natale, R., Garon, E.B., Nakagawa, K., Liu, F., Thiyagarajah, P., Peters, S., Rizvi, N.A.

Get full text

Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro) by Herbst, R.S., Garon, E.B., Kim, D.-W., Chul Cho, B., Pérez Gracia, J.L., Han, J.-Y., Dubos Arvis, C., Majem, M., Forster, M., Monnet, I., Novello, S., Szalai, Z., Gubens, M.A., Su, W.-C., Ceresoli, G.L., Samkari, A., Jensen, E., Lubiniecki, G.M., Baas, P.

Get full text

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? by Rodriguez Abreu, D., Garassino, M.C., Esteban, E., Speranza, G., Felip, E., Domine, M., Hochmair, M.J., Powell, S.F., Cheng, S.Y.-S., Bischoff, H., Peled, N., Hui, R., Reck, M., Garon, E.B., Boyer, M., Grossi, F., Jennens, R., Yang, J., Pietanza, M.C., Gadgeel, S.M.

Get full text

Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results by Nakagawa, K., Garon, E.B., Paz-Ares, L., Ponce, S., Corral Jaime, J., Juan Vidal, O., Nadal, E., Kiura, K., He, S., Treat, J., Dalal, R., Lee, P., Reck, M., Novello, S.

Get full text

KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? by Rodriguez Abreu, D., Garassino, M.C., Esteban, E., Speranza, G., Felip, E., Domine, M., Hochmair, M.J., Powell, S., Cheng, S.Y.-S., Bischoff, H.G., Peled, N., Hui, R., Reck, M., Garon, E.B., Boyer, M., Grossi, F., Jennens, R., Yang, J., Pietanza, M.C., Gadgeel, S.

Get full text

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors by Garon, E.B., Wong, D.J., Schneider, J.G., Aljumaily, R., Korn, W.M., Patel, M.R., Autio, K.A., Papadopoulos, K.P., Naing, A., Gabrail, N., Munster, P.N., Goldman, J., Hung, A., Oft, M., Leveque, J., Spigel, D.R.

Get full text

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer by Gandhi, Leena, Rodríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, De Angelis, Flávia, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven F, Cheng, Susanna Y.-S, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M. Catherine, Garassino, Marina C

“…The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival…”
Get full text

Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study by Wolf, J., Garon, E.B., Groen, H.J.M., Tan, D.S.W., Le Mouhaer, S., Riester, M., Ji, L., Robeva, A., Fairchild, L., Boran, A., Heist, R.S.

Get full text